TIDMORPH

RNS Number : 1559B

Open Orphan PLC

29 September 2022

Open Orphan plc

("Open Orphan" or the "Company")

CEO share purchase

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has received notification that on 29 September 2022, Yamin 'Mo' Khan, Chief Executive Officer of the Company, purchased 510,204 ordinary shares of 0.1 pence each in the capital of the Company ("Shares") at a price of 9.8 pence per Share. Following the purchase of shares Mo holds 510,204 ordinary shares representing approximately 0.08 per cent of the Company's issued ordinary capital.

Yamin 'Mo' Khan, Chief Executive Officer of Open Orphan plc, said: "The purchase of shares in the Company demonstrates both my commitment and my confidence in our long-term growth strategy. Since my appointment as CEO in February 2022, we have made significant progress, delivering continued growth and a record orderbook valued at c.GBP80m as of 1 September, which provides excellent forward visibility into H2 2022 and 2023."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

For further information please contact:

 
 Open Orphan plc                                                       +44 (0) 20 7756 1300 
 Yamin Khan, Chief Executive Officer 
 
 Liberum Capital (Nominated Adviser 
  and Joint Broker)                                                    +44 (0) 20 3100 2000 
 Ben Cryer/ Edward Mansfield/ Phil 
  Walker/ Will King 
 
 finnCap plc (Joint Broker)                                            +44 (0) 20 7220 0500 
 Geoff Nash / James Thompson / Richard 
  Chambers 
 
 Davy (Euronext Growth Adviser and 
  Joint Broker)                                                         +353 (0) 1 679 6363 
 Anthony Farrell 
 
 Walbrook PR (Financial PR & IR)           +44 (0)20 7933 8780 or openorphan@walbrookpr.com 
  Stephanie Cuthbert / Phillip                      +44 (0) 7796 794 663 / +44 (0) 7867 984 
  Marriage /                                                                          082 / 
  Louis Ashe-Jepson                                                    +44 (0) 7747 515 393

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is changing its name to hVIVO plc (AIM and Euronext: HVO), which is expected to take effect on the AIM market of the London Stock Exchange and the Euronext Growth Exchange market on 26 October 2022.

hVIVO is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.

The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of new models, such as malaria and COVID-19, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Yamin Khan 
     -------------------------------  ---------------------------------- 
 2.   Reason for the Notification 
     ------------------------------------------------------------------- 
 a)   Position/status                  Chief E xecutive Officer 
     -------------------------------  ---------------------------------- 
 b)   Initial notification/amendment   Initial notification 
     -------------------------------  ---------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                             Open Orphan plc 
     -------------------------------  ---------------------------------- 
 b)   LEI                              213800VT5KBM7JLIV118 
     -------------------------------  ---------------------------------- 
 4.   Details of the transaction(s):section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv)each place where transactions have been 
       conducted 
     ------------------------------------------------------------------- 
 a)   Description of the Financial     Ordinary shares of 0.1 pence each 
       instrument, type of 
       instrument 
     -------------------------------  ---------------------------------- 
      Identification code              ESVUFR 
                                        ISIN GB00B9275X97 
     -------------------------------  ---------------------------------- 
 b)   Nature of the Transaction        Purchase of ordinary shares 
     -------------------------------  ---------------------------------- 
 c)   Price(s) and volume(s)            Price        Volume 
                                         9.8 pence    510,204 
                                                     -------- 
     -------------------------------  ---------------------------------- 
 d)        Aggregated information      As above 
             *    Aggregated volume 
 
 
             *    Price 
     -------------------------------  ---------------------------------- 
 e)   Date of the transaction          29/09/2022 
     -------------------------------  ---------------------------------- 
 f)   Place of the transaction         London Stock Exchange 
     -------------------------------  ----------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSEWSAUEESEEU

(END) Dow Jones Newswires

September 29, 2022 04:30 ET (08:30 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Hvivo Charts.
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Hvivo Charts.